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Abstract We evaluated clinically and sonographically the
effects of etanercept therapy in patients with rheumatoid
arthritis (RA) over 12 months of treatment. Eighteen patients
affected byRAwhowere non-responders or partial responders
to disease modifying therapy were commenced on Etanercept
treatment. Before starting therapy (T0) and at 12 months (T1),
the following parameters were evaluated: erythrocyte sedi-
mentation rate (ESR), C-reactive protein (CRP), visual
analogue scale (VAS) for pain, number of painful and swollen
joints, health assessment questionnaire (HAQ) and disease
activity score in 28 joints (DAS 28). Musculoskeletal
ultrasound (US) was performed in the following joints: second
and fifthmetacarpophalangeal, third interphalangeal,wrist and
knee joints and a semiquantitative score (0–3) calculated and
used to indicate the presence of a localised inflammatory
process (synovitis, tenosynovitis, bursitis) and/or structural
damage (bone erosion and cartilaginous change). An overall
score was calculated based on the sum of the single scores to
obtain a comprehensive score indicative of the global
pathological change. The US global scores significantly
reduced between T0 and T1 (p<0.0001). The following
laboratory and clinical parameters also significantly reduced:
ESR (p<0.0001), CRP (p<0.02), VAS (p<0.001), number
of total swollen joints (p<0.001), number of total painful
joints (p<0.01), HAQ scores (p<0.05) and DAS 28 (p<
0.0001). A positive response to treatment with Etanercept
was demonstrated both by US examination of several joints
and by clinical evaluation of several parameters. US is a
useful tool in the monitoring of biologic therapy in RA,
assessing both inflammatory and destructive changes.
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Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory
rheumatic disease with systemic features in which the
principal targets of the inflammatory process are articular
and peri-articular tissues [1]. In recent years, rheumatolog-
ical research has witnessed a revolution related to the study
of molecules involved in the inflammatory process and
primarily the identification of the key role of tumour
necrosis factor alpha (TNFα) [2]. Its capacity to stimulate
the production and secretion of pro-inflammatory cyto-
kines, regulate the expression of adhesion molecules on
endothelial cells, control the migration of leucocytes to sites
of inflammation, increase the production of metalloprotein-
ases from synovial macrophages and inhibit the production
of proteoglycans has been well demonstrated to date [3].
Moreover, TNFα stimulates neovascularisation of synovial
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tissue, a phenomenon which correlates with the level of
local inflammatory activity [4]. In essence, TNFα repre-
sents a key molecule in the activation and perpetuation of
the inflammatory process within joints and systemically in
RA, leading subsequently to joint erosion and permanent
structural damage [5].
In light of the fundamental role played by such cytokine
in the pathogenesis of the inflammation seen in RA,
research has concentrated on implementing new pharmaco-
logical strategies to directly antagonise TNFα, with the aim
of blocking or slowing down its molecular impact [6–9].
Enbrel is one agent which inhibits the soluble TNFα
receptor. Randomised double-blind control trials have
demonstrated the safety, tolerability and the reduction in
disease activity of anti-TNFα therapy [10]. In RA, TNFα
blockade results in an improvement in the number and
severity of joints involved, the indices of inflammation and
the parameters of disease activity both compared to placebo
and compared with other disease-modifying drugs particu-
larly methotrexate [11].
Ultrasound (US) of joints and tendons is a useful
imaging method in the diagnosis and follow-up of
rheumatic disorders [12]. It can demonstrate changes in
the soft tissues particularly hypertrophy of the synovial
membrane, joint inflammation, tenosynovitis and bursitis
[13]. Moreover, with the advent of power Doppler, US is
capable of revealing the extent of synovial flow in presence
of neovascularisation and therefore the increase in perfu-
sion of the synovial membrane in cases of synovitis [14].
As a result, it is now possible to demonstrate the level of
inflammatory activity present within synovial tissue, differ-
entiating between acute and chronic inflammation [15]. US
is of particular benefit when searching for bone erosion and
cartilaginous change in early phases of the disease process,
thereby allowing a diagnosis to be confirmed and the
progression of the disease to be followed [16]. Furthermore,
multiplanar scanning permits examination of superficial
areas which cannot be studied satisfactorily with conven-
tional X-ray [17, 18].
Only a few studies have been published to date in which
the response to biologic therapy has been followed. The
results obtained have, however, underlined the potential
role for US in the monitoring treatment response [19–21].
Unfortunately, the small number of patients and the brevity
of follow-up make further studies necessary.
The object of this study was to evaluate, by means of
US, the effects of etanercept therapy in RA after 1 year and
correlate these findings with clinical and laboratory indices.
Materials and methods
Eighteen consecutive patients, 4 men and 14 women,
receiving etanercept (25 mg subcutaneously twice weekly)
plus methotrexate (10–15 mg weekly) and/or hydroxy-
chloroquine (400 mg daily) and/or salazopyrin (2 g daily)
and non-steroid anti-inflammatories (diclofenac 50–100 mg
daily or indomethacin 50–100 mg daily or nimesulide 100–
200 mg daily) and steroids (methylprednisolone 4–8 mg
daily) for RA and fulfilling the American Rheumatology
Association diagnostic criteria were studied. All patients
were non-responders or partial responders to disease-
modifying therapy. The mean age was 50.8 (range 31–69)
with mean disease duration of 13.05 years (range 3–31).
This study was conducted only in one center, the
Rheumatology Unit of “Sapienza” University of Rome, in
compliance with the protocol and good clinical practices,
following the routinely monitoring procedures performed in
our unit for patients with arthritis.
Table 1 US, clinical and laboratory parameters
Joints and parameters studied with US
Joints studied
(bilaterally)
II MCP/V MCP/III PIP/wrist/knee
US parameters
evaluated
Synovial membrane: proliferation/
thickness/hyper-perfusion (power Doppler)
Synovial fluid: effusion
Tendons and bursae: tenosynovitis
and bursitis
Bone: erosions
Cartilage: cartilagenous change
Score 0–3
Clinical and
laboratory parameters
ESR/CRP/patient VAS/HAQ/number
of tender joints/number of swollen
joints/DAS 28
Table 2 Subdivision of all US, clinical and laboratory parameters into four classes of severity
Class US ESR VAS HAQ No pain joints No swollen joints DAS 28
I <10 ≤10 ≤30 <0.5 ≤6 ≤3 <2.6
II ≥10<20 >10<25 >30<55 ≥0.5<1 >6≤15 >3≤7 ≥2.6<3.2
III ≥20<30 ≥25<40 ≥55<80 ≥1<1.5 >15≤24 >7≤10 ≥3.2<5.1
IV ≥30 ≥40 ≥80 ≥1.5 >24 >10 ≥5.1
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US examination
In all patients, the following joints were studied bilaterally:
second and fifth metacarpophalangeal (MCPs), third inter-
phalangeal (PIP), wrist and knee. The joints evaluated were
chosen because they are commonly involved in RA, and
they can be reliably assessed by US. The US examination
was performed using a Philips/HP Image Point HX
machine with a 10-MHz linear probe for knee joints and a
14-MHz probe for the hands and wrists. In addition, power
Doppler was used with the following settings: PRF varying
from 700–1,000 Hz (according to the joint studied) gain
18–30 dB, low filter. The examination was performed
before the initiation of etanercept (T0) and after 52 weeks
(T1). The US study was performed by an experienced
rheumatologist sonographer (AI) who was blinded to the
clinical and laboratory findings in each patient.
In every joint, a multiplanar scanning technique [17, 18]
was used and the presence of inflammation documented in
joints and or peri-articular tissues (joint effusion, synovial
proliferation, hyperaemia in the synovial tissue, tenosyno-
vitis and bursitis) together with the presence of permanent
damage (bone erosions and cartilaginous abnormalities).
The changes within each articular and peri-articular
structure were recorded as being present in accordance
with the reported definitions in the literature [22, 23]. For
all the changes, a semiquantitative score (0–3) was used for
each structure examined indicating the degree of inflam-
matory activity and structural damage (0 = normal; 1 = mild
change; 2 = moderate change; 3 = severe change) and the
subsequent summed total used as an indicator of global
change at each time point. An increase in score from T0 to
T1 was considered indicative of global deterioration in the
pathological process, whilst a reduction was indicative of
an overall improvement.
Clinical evaluation
The clinical and laboratory parameters measured at T0 and
T1 are listed in Table 1.
Table 3 Results for all patients at T0 and T1
Patients US
T0
US
T1
ESR
T0
ESR
T1
CRP
T0
CRP
T1
VAS
T0
VAS
T1
HAQ
T0
HAQ
T1
Pain
T0
Pain
T1
Swel
T0
Swel
T1
DAS
28 T0
DAS
28 T1
BC 34 26 16 19 neg neg 75 68 1.25 2 13 15 4 3 5.57 5.67
BL 18 8 30 27 pos neg 67 21 2 1 21 1 8 3 6.75 3.77
BN 21 13 43 5 pos pos 40 30 1.38 0.75 8 10 7 4 4.62 4.43
CP 27 13 22 11 pos pos 95 53 1.625 1 25 6 16 6 6.92 4.15
CF 18 12 42 19 pos neg 55 40 0.5 0.5 16 10 5 5 6.25 5.02
CP 17 6 40 18 neg neg 20 10 0.125 0.125 1 1 1 0 3.7 2.72
CA 27 16 45 15 pos neg 81 36 1.125 0.625 14 9 6 0 6.58 4.08
DE 21 8 10 8 neg neg 70 35 1.875 0.25 20 14 6 0 5.78 4.04
DM 31 7 30 17 pos neg 70 0 1.5 0.625 15 0 4 0 5.32 1.98
LR 21 4 62 18 pos pos 73 40 2 2 27 11 11 8 7.88 5.23
MS 20 12 28 22 neg neg 40 33 1 1 22 10 12 8 6.42 5.34
PP 17 8 40 33 pos neg 100 50 1.5 1.125 2 4 2 1 5.17 4.55
PA 25 8 21 11 neg neg 48 20 1 0 1 0 2 0 3.61 1.92
PL 21 16 76 50 pos neg 70 67 1.375 1 6 1 4 0 5.94 4.24
PS 15 5 32 10 neg neg 50 0 1.25 0 19 3 11 1 6.92 2.86
SM 30 13 40 22 pos neg 90 27 2 5 29 4 12 1 7.79 5.1
Table 4 Results (mean and
median) at T0 and T1
t Test for dependent samples.
Data are presented as mean±
SD or median (25th–75th
percentile)
aWilcoxon signed rank test
b Chi-square test
Variable T0 (n=18) p T1 (n=18)
Age (years) 50.8(31–69) >0.05 51.8 (32–70)
USa 21 (18–27) <0.0001 11.2 (8–13)
CRP>0.5 mg/dl n (%)b 8 (44) <0.02 3 (17)
ESR 35±17 <0.0001 19±12
VASa 70.0 (50–70) <0.001 33.5 (21–50)
HAQa 1.38 (1,12–1,87) <0.05 1.03(0.37–1.12)
Painful jointsa 14.5 (8–21) <0.01 6.5 (1–10)
Swollen jointsa 6 (4–11) <0.001 1 (0–5)
DAS 28 5.9±1.2 <0.0001 4.1±1.4
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For each US, clinical and laboratory parameter 4 degrees
of severity were assigned to the changes to grade the effects
of therapy (Table 2).
Statistical analysis
Data were reported as mean values±standard deviations or
as median values with the inter-quartile ranges in cases of
variables with non-standard distribution. Appropriate sta-
tistical tests were used to analyse the data. In particular,
normally distributed variables were analysed using the
Student’s t test for unpaired data and Pearson correlation.
For all other nonparametric data, the following tests were
used (Mann–Whitney U test, Kruskal–Wallis, analysis of
variance and Spearman correlation test). The differences in
percentages were analysed using the chi-squared test.
Statistical significance was taken at a p value<0.05. All
calculations were made using IBM ‘Statistica’ (StatSoft,
Tulsa, OK, USA) software.
Results
The results of this study are summarised in Tables 3 and 4
and Fig. 1.
US evaluation demonstrated a significant reduction
(median changes=−10; p<0.0001) in the US global score
(sum of the semiquantitative score or each structure
examined indicating the degree of inflammatory activity
and structural damage) from T0 to T1. In particular, before
starting therapy, the median US global score was 21 [inter-
quartile ranges (IQR), 18–27] and after 1 year of etanercept
therapy was reduced to 11.2 (IQR, 8–13). The evaluation of
the knee joint is shown in Fig. 2 at T0 and T1.
CRP values significantly decreased after 12 months. Of
the 11 patients with an elevated CRP at baseline, eight had
normal values at T1 and three remained high (p<0.02).
Erythrocyte sedimentation rate (ESR) also fell significantly
(p<0.0001) from a mean of 35(±17 mm/h) at T0 to 19
(+SD 12) at T1. The median VAS fell significantly (p<
0.001) from 70 (IQR, 50–70) at T0 to 33.5 (IQR, 21–50) at
T1. Median Health assessment questionnaire (HAQ) values
fell significantly (p<0.05) from 1.38 (IQR, 1.12–1.87) at
baseline to 1.03 (IQR, 0.37–1.12) at 1 year. The number of
painful total joints changed significantly (p<0.01) from a
median of 14.5 (IQR, 8–21) at baseline to 6.5 (IQR, 1–10)
at T1. Similarly, the median number of total swollen joints
also fell significantly (p<0.001) from 6 (IQR, 4–11) at
baseline to 1 (IQR, 0–5) at T1. The mean DAS 28 scores
fell significantly (p<0.0001) from 5.9 (±1SD, 1.2) to 4.1
(±1SD, 1.4) at 1 year. The subclasses in the degree of
change demonstrated in all the parameters evaluated more
severe involvement (III, IV) at baseline and less severe
degrees of involvement (I, II) at 1 year.
Discussion
In recent years, the role of US as a diagnostic tool and as a
mode of monitoring therapy in rheumatic disease has been
progressively confirmed. It has enabled the exploration of
various articular and peri-articular structures [24] together
with local neovascularisation, thanks to power Doppler. It is
now possible to identify and monitor the progression of
active inflammation.
b
*
*
a
Fig. 2 Knee US. Supra-patellar transverse scan. a At T0, an effusion
(*) and synovial proliferation were present in the supra-patellar bursa.
b At T1, a reduction in the size of effusion (*) and synovial
proliferation was seen
a
b
Fig. 1 Subdivision into classes of severity of the changes seen in all the
parameters evaluated. A response to therapy was demonstrated in patients
who had more severe changes (classes III and IV) at T0 and less severe
changes (classes I and II) at T1. The p values were respectively: US
global score, p<0.0001; CRP, p<0.02; ESR, p<0.0001; VAS, p<0.001;
HAQ, p<0.05; number of total painful joints, p<0.01; number of total
swollen joints, p<0.001; DAS 28, p<0.0001
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To date, very few scientific papers have documented the
use of US in the monitoring of biologic therapy. D’Agostino
et al. [25] demonstrated a significant reduction in synovial
perfusion within the Achilles insertion in two patients treated
with infliximab (3 mg/kg at time 0, 2 and 6 weeks) after
14 weeks. Ribbens et al. [26] subsequently showed a clear
reduction in synovitis and power Doppler signal in the small
joints of the hand in 11 patients treated with infliximab for
6 weeks. Furthermore, in 2004, a randomised placebo-
controlled trial compared radiographic methods in the
evaluation of the joints of the hand and feet with US in
patients with RA treated with methotrexate and infliximab or
placebo [27]. This study showed a reduction in inflammation
and retardation of joint destruction in patients who had been
randomised to receive infliximab both in terms of radio-
graphic and sonographic findings. At present the effects of
etanercept in the treatment of patients with RA has not been
extensively studied.
Hau et al. [28] studied the effects of etanercept (25 mg×2/
week) in five patients after 1 month of therapy and showed a
significant reduction in synovial perfusion with power
Doppler at the level of the second MCP joint. A further
study evaluated the changes in synovial perfusion in 11
patients with RA treated with etanercept (50 mg/week) at the
level of the wrist and the MCP joints and documented an
important initial reduction in perfusion after 1 week of
treatment [29]. More recently, 12 patients with RA and eight
with psoriatic arthritis and knee synovitis treated with
etanercept had a significant reduction in power Doppler
signal which correlated with reductions in indices of disease
activity including ESR and CRP. This improvement in
synovitis was maintained for 12 months of biologic therapy
and was confirmed by the reduction in thickness of the
synovial membrane sonographically [30].
The results of these studies underline the emerging role of
greyscale US and power/color/contrast-enhanced Doppler in
the evaluation of anti-inflammatory efficacy of biologic
therapy with infliximab and etanercept in chronic arthritis,
most notably RA [31–35]. Unfortunately, these studies have
been limited by the number of patients evaluated together
with the short period of follow-up. With this in mind, our
study followed 18 patients with RA treated with etanercept
and monitored sonographically, clinically and serologically
over a 52-week period. We have clearly demonstrated a
significant reduction in US score calculated on the joint
examination. The importance of these data was confirmed by
a parallel reduction in all the clinical and laboratory indices
of disease activity. Furthermore, it seems that the response of
US parameters is greater than DAS 28. The results of our
study are supportive of those presented in other reports
where US was used to monitor disease activity. We were
able, however, to demonstrate this in a wider range of
anatomical targets than in previous studies [28–30]. To our
knowledge, this study represents the first attempt to
investigate the effects of biologic therapy on multiple
parameters in various joints affected by a chronic arthropa-
thy. Then, US appears to be a valuable tool for the
assessment of the response to treatment in RA, and it has
many advantages over other diagnostic methods and clinical
indices of disease activity such as the low cost, non-
invasiveness and possibility of a contemporaneous assess-
ment of inflammatory and structural changes. The close
relationship between our US findings and the standardly
used clinical and serological indices of disease activity
strengthen further the case for using US as one of the
investigations of choice in the monitoring of biologic therapy
in RA [36–46].
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